Biopharma's High Performers 2014

Pharmaceutical Executive

Accenture has launched the latest version of its annual study of the biopharmaceutical industry.

Accenture has launched the latest version of its annual study of the biopharmaceutical industry. The High Performance Business (HPB) report analyses  the long-term performance of the 16 largest pharma companies globally, highlighting industry trends, pharmaceutical business performance analysis, and potential implications for the industry.

Some highlights from this year’s study include:

  • R&D pipeline is output up - pharma has entered a period of markedly improved R&D output - but the productivity crisis not fixed.

  • In the last two years, FDA New Molecular Entity (NME) approvals are up approximately 30% on the last decade; they are expected to remain elevated over the next 5 years.

  • In the emerging markets recent and upcoming launches are forecast to drive up to $140 billion in growth over the next 5 years. Strong growth from new products and emerging markets will help to overcome the $103 billion in revenue expected to be lost from patent expired drugs, making a positive overall trajectory for growth for the industry.

  • New product launches are entering an unprecedentedly tough payer climate in developed markets.

  • High Performers are more successfully bringing new science to market through launch capabilities that demonstrate whole system patient outcomes.

  • High Performers display five key attributes that set them apart from their competitors:
    - They continue to harness collaborative R&D models.
    - They are committed to applying science to product launches focused on outcomes for specific patient groups.
    - They use flexible pricing strategies to meet patient population.
    - They display a mastery of multichannel marketing and patient services to reinforce patient outcomes.
    - They are fine tuning local operations to succeed in emerging markets.

For more information, visit the Accenture website.